Key result
This review outlines pharmacokinetic and pharmacodynamic changes in aging and provides guidance on the prudent use, adverse effects, and avoidance of specific cardiovascular medications in the elderly.
This review highlights the pharmacokinetic and pharmacodynamic changes in the elderly that necessitate careful selection and dosing of cardiovascular medications.
Answers are grounded in this paper and cite their sources.
May guide age-adjusted CV drug selection in elderly; extends prior syntheses but leaves open need for prospective validation.
Pharmacokinetic considerations in the elderly include absorption, bioavailablility, drug distribution, half-life, drug metabolism, and drug excretion. There are numerous physiologic changes with aging that affect pharmacodynamics with alterations in end-organ responsiveness. This article discusses use of cardiovascular drugs in the elderly including digoxin, diuretics, beta-adrenergic blockers, angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, nitrates, calcium channel blockers, alpha-adrenergic blockers, antiarrhythmic drugs, lipid-lowering drugs, and anticoagulants. This article also discusses the adverse effects of cardiovascular drugs in the elderly, medications best to avoid in the elderly, and the prudent use of medications in the elderly.
No takes yet. Share an insight, caveat, or question.
Aronow et al. (2007) conducted a review in Cardiovascular disease in the elderly. Cardiovascular drugs was evaluated. This review outlines pharmacokinetic and pharmacodynamic changes in aging and provides guidance on the prudent use, adverse effects, and avoidance of specific cardiovascular medications in the elderly.
Synapse has enriched 10 related papers. Consider them for comparative context: